Metformin's case as an anti-ageing drug now rests on three null results
Twenty-one years of cancer follow-up, multimorbidity data to 2021, and a randomised trial in frail older adults. In each, metformin did not beat placebo. Lifestyle change did.
A philanthropist is paying for the rapamycin trial no drug company would fund
A $12 million gift will test whether low-dose rapamycin changes the transition to frailty in adults over 65 — the first study of the drug designed around an outcome rather than a biomarker.
Two October papers on creatine in older adults point at strength, not muscle mass
A meta-analysis of 20 trials found a two-kilogram gain in one-rep max and no effect on bone density. A small crossover trial found functional strength gains largely independent of muscle mass.